AndroMETa-CRC-560: An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with Refractory Metastatic Colorectal Cancer

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521712-19-00

Enrollment

Registered

2026-06-29

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Brief summary

Phase 3: Objective Response (OR) as assessed by Blinded Independent Central Review (BICR), Phase 3: Overall Survival (OS)

Detailed description

Phase 3: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR), Phase 3: Duration Of Response (DoR) as assessed by BICR, Phase 3: Disease Control (DC) as assessed by BICR:, Phase 3: Change from baseline in the EORCT QLQ-C30 physical functioning domain at Week 13, Phase 3: Change from baseline in the remaining EORCT QLQ-C30 domains

Interventions

DRUGTelisotuzumab adizutecan

DRUGTRIFLURIDINE

DRUGCOMBINATIONS

DRUGBEVACIZUMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Secondary

Measure	Time frame
Phase 3: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR), Phase 3: Duration Of Response (DoR) as assessed by BICR, Phase 3: Disease Control (DC) as assessed by BICR:, Phase 3: Change from baseline in the EORCT QLQ-C30 physical functioning domain at Week 13, Phase 3: Change from baseline in the remaining EORCT QLQ-C30 domains	—

Primary

Measure	Time frame
Phase 3: Objective Response (OR) as assessed by Blinded Independent Central Review (BICR), Phase 3: Overall Survival (OS)	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 1, 2026